BresMed Health Solutions Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BresMed Health Solutions Ltd - overview
Established
2006
Location
Sheffield, South Yorkshire, UK
Primary Industry
Pharmaceuticals
About
BresMed Health Solutions Ltd is a firm specializing in health economics and outcomes research (HEOR), delivering data analytics services and consulting to enhance healthcare decision-making processes. BresMed Health Solutions Ltd, founded in 2006, is based in Sheffield, UK. The company focuses on health economics and outcomes research, serving pharmaceutical and biotechnology companies by providing advanced data analytics and consulting services. In February 2020, BresMed was acquired by Arsenal Capital Partners' Value Demonstration Platform.
The company's founder's history and prior ventures are not publicly available. BresMed has completed one deal to date, with the most recent deal occurring on 26 February 2020. BresMed specializes in delivering health economics and outcomes research (HEOR) solutions that enhance decision-making for healthcare stakeholders. Their services include data analytics aimed at demonstrating product value, as well as bespoke consulting that aids clients in navigating complex healthcare environments.
Their offerings address critical issues such as cost-effectiveness and patient outcomes, primarily in Europe and North America, for healthcare professionals, policymakers, and market access teams. In 2023, BresMed generated a revenue of USD 278. 22 mn and achieved an EBITDA of USD 13. 54 mn.
The company's revenue model includes consulting fees and project-based contracts focused on health economic modeling and market access strategy, reinforcing long-term partnerships with pharmaceutical and biotech firms. While specific upcoming products or services have not been detailed, BresMed plans to leverage its recent acquisition to expand its presence in the healthcare market. The firm may target further geographical expansion in North America and Europe, utilizing insights from its strategic deal in February 2020 to enhance its offerings and client relationships. The funding received through this acquisition will likely support these growth initiatives as they seek to optimize their service portfolio and reach new clients.
Current Investors
Value Demonstration Company
Primary Industry
Pharmaceuticals
Sub Industries
Consulting Services, Pharmaceutical Research & Development
Website
www.bresmed.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
BresMed Health Solutions Ltd - financials
| Fiscal Year Ended | Mar 31, 2019 | Mar 31, 2020 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 15,313,076.647 | 13,692,581.059 | 12,255,109.544 | - | - | - |
| % Revenue Growth (YoY) | - | (10.6%) | - | - | - | - |
| EBITDA (USD) | 52,819.315 | (1,877,949.074) | 769,962.013 | - | - | - |
| Operating Income (USD) | (55,811.639) | (2,055,248.23) | 496,044.354 | - | - | - |
| Operating Margin | (0.4%) | (15.0%) | 4.0% | - | - | - |
| % EBITDA Margin | 0.3% | (13.7%) | 6.3% | - | - | - |
| NET Income (USD) | (178,088.589) | (1,878,441.211) | 255,318.098 | - | - | - |
| % Net Margin | (1.2%) | (13.7%) | 2.1% | - | - | - |
BresMed Health Solutions Ltd - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | BresMed Health Solutions Ltd | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.